-
Central Fill Pharmacy Automation Market Projected To Witness Substantial Growth, 2024-2031: Omnicell, Inc, Neuralstem
11 Sep 2024 11:08 GMT
… advancements allow for more accurate drug dispensing, real-time tracking, and … )
◘ GSE Scale Systems
◘ Manchac Technologies
◘ Neuralstem
Deep-dive Analysis:
The Report …
-
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
09 Oct 2019 13:03 GMT
… )
Neon Therapeutics Inc (NASDAQ: NTGN)
Neuralstem, Inc. (NASDAQ: CUR)
Novelion Therapeutics …
FDA Approves Clinuvel's Drug For Erythropoietic Protoporphyria Patients
Australian … .
Viela Out-Licenses Autoimmune Disorder Drug To Mitsubishi Tanabe
Viela Bio …
-
The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering
04 Oct 2019 11:40 GMT
… Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)
Neuralstem, Inc. (NASDAQ: CUR)
Obseva … Arbutus Halts Hepatitis B Drug Study
Arbutus Biopharma Corp … toxicities and no anti-drug antibodies.
Meanwhile, Aptevo … review of an investigational drug intended to treat a …
-
The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission
16 Aug 2019 11:54 GMT
… reporting positive results for its drug to treat hepatorenal syndrome 1 … /S ADR (NASDAQ: MTFB)
Neuralstem, Inc. (NASDAQ: CUR)(reacted to …
-
The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
14 Aug 2019 12:21 GMT
… )
Meridian Bioscience, Inc. (NASDAQ: VIVO)
Neuralstem, Inc. (NASDAQ: CUR)
Nevro Corp …
Regeneron's Bad Cholesterol Drug Meets Primary Endpoint In Late …
-
The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation
23 Jul 2019 11:48 GMT
… late-stage trial of a drug combo the company is … MYOV)
Neovasc Inc (NASDAQ: NVCN)
Neuralstem, Inc. (NASDAQ: CUR)
Nuvectra Corp …
ACADIA's Schizophrenia Drug Flunks a Late-stage Study … Gets Breakthrough Therapy Designation For Drug to Treat Liver Cancer
…
-
Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors
18 Jul 2019 15:43 GMT
… shared commitment here at Neuralstem to improve patient outcomes. … scientist focused on new drug development, she subsequently worked … School of Medicine.
About Neuralstem
Neuralstem is a clinical-stage … high unmet medical need. Neuralstem's diversified …
-
Neuralstem appoints Ken Carter as executive chairman
19 Dec 2018 13:20 GMT
… brings a wealth of drug development expertise and executive leadership … a pipeline of cancer drug candidates based on a … Company and Dr Carter.
Neuralstem is a clinical-stage biopharmaceutical … high unmet medical need. Neuralstem’s diversified portfolio of …
-
Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board
18 Dec 2018 12:00 GMT
… 18, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a … brings a wealth of drug development expertise and executive … a pipeline of cancer drug candidates based on a … and Dr. Carter. About Neuralstem Neuralstem is a clinical-stage biopharmaceutical …
-
The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut
13 Nov 2018 13:23 GMT
… )
Miragen Therapeutics Inc (NASDAQ: MGEN)
Neuralstem, Inc. (NASDAQ: CUR)
Oncomed Pharmaceuticals … New Phase 2 Data For Drug to Treat Cholesterol, Liver Fat …